Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
26.98 K
Value Traded
404.67
Short % Float
-
Days to Cover
1.0
-28.57%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.05 M
EPS (TTM)
-
P/E Ratio
-
Ent. Value
23.23 M
Total Shares
70.19 M
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
EMMA Catalyst Timeline
Dated clinical, regulatory and corporate events for Emmaus Life Sciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How EMMA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every EMMA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LEE WILLIS CDirector, Officer (CEO) | Buy | 100,000 690,167 held | $0.05 | 08/31/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in EMMA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in EMMA for Q2 2026. | ||||
Ownership Trends
EMMA Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
9.9K
Shares Sold Short
+229.2% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
26.0K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How EMMA ranks across every disease it competes in
Competitive Position is a premium feature
See how EMMA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialEMMA News
-EMMA
Nov 12, 2026▼ -31.5%today
Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa
Emmaus Life Sciences is advancing its strategy in the Middle East by launching real-world evidence initiatives and entering the North African market through a partnership in Libya. The initiatives focus on generating region-specific data on Endari® for sickle cell disease, aiming to improve treatment outcomes and support the company's international growth. Marketing authorizations have been secured across five Middle Eastern markets.
Read more →-EMMA
Aug 31, 2026Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer
Emmaus Life Sciences has signed an exclusive option agreement with Cedars-Sinai to evaluate L-glutamine oral powder combined with chemotherapy for treating pancreatic ductal adenocarcinoma (PDAC). This follows the GlutaPanc trial results, highlighting the need for new treatment options in this challenging area. The efficacy and safety of L-glutamine for this use remain unproven.
Read more →-EMMA
Aug 14, 2026Emmaus Life Sciences Reports Quarterly Financial Results
Emmaus Life Sciences reported a strong financial performance for Q2 2026, with net revenues reaching $6.3 million, a 124% increase from the previous year. The company also achieved a net income of $1.3 million, driven by the recognition of revenue from a licensing agreement with NeoImmuneTech. Operating expenses decreased significantly, contributing to improved profitability.
Read more →About Emmaus Life Sciences, Inc.
BIOPHARMAWATCH ELITE
Trade the next EMMA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime